Skip to content

Advertisement

  • Poster presentation
  • Open Access

P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model

  • 1,
  • 1,
  • 1,
  • 2,
  • 1,
  • 2,
  • 2,
  • 2,
  • 1 and
  • 1
Journal for ImmunoTherapy of Cancer20142 (Suppl 2) :P42

https://doi.org/10.1186/2051-1426-2-S2-P42

  • Published:

Keywords

  • Tumour Antigen
  • Gastric Tumor
  • Positive Tumour Cell
  • mGC8 Cell
  • Bispecific Antibody

Background

A limiting step for adoptively transferred tumour-specific T cells is their recruitment from the blood circulation to the proximity of tumour cells and subsequent engagement in direct tumour cell contact. We hypothesised that a bispecific antibody recruiting T cells to a target antigen on tumour cells could enhance T-cell-tumour interaction and thus increase the efficacy of adoptively transferred T cells.

Material and methods

A new bispecific murine IgG2a antibody (BsAb) was generated that recognises EpCAM as a tumour antigen and truncated EGFR (D-EGFR) as an inert surface marker protein on transduced T cells. T cells from transgenic mice for TCR specific for the SV40 large T antigen (TCR-1) were retrovirally transduced with D-EGFR. S.c. tumors were induced in C57Bl/6 mice by injecting mGC8 cells derived from a syngeneic large T antigen expressing EpCAM-positive gastric tumor.

Results

In vitro, the BsAb increased (4-fold) binding of transduced T cells to EpCAM positive tumour cells. In the presence of the BsAb, tumour-directed T cells efficiently lysed EpCAM-positive cells (83 % at a 10:1 effector to target ratio). In vivo, the antibody reached EpCAM+ tumour cells as evidenced by immunofluorescence. mGC8 tumour-bearing mice were treated twice with a combination of the BsAb and transduced TCR-I T cells. Tumour growth was significantly reduced for over 30 days (n=12) compared with control groups (transduced T-cells or BsAb alone) and survival was prolonged by > 30 days (p<0.001).

Conclusions

Co-administration of a BsAb bridging adoptively transferred tumour-specific T cells via an inert surface molecule to a tumour-associated surface antigen enhances the efficacy of therapeutic T cell transfer.

Authors’ Affiliations

(1)
Division of Clinical Pharmacology, Munich, Germany
(2)
Roche Diagnostics GmBH, Discovery Oncology, Penzberg, Germany

Copyright

Advertisement